Mueller Stefan O, Hall Julie M, Swope Deborah L, Pedersen Lars C, Korach Kenneth S
Laboratories of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
J Biol Chem. 2003 Apr 4;278(14):12255-62. doi: 10.1074/jbc.M203578200. Epub 2003 Jan 22.
The two known estrogen receptors, ERalpha and ERbeta, are hormone-inducible transcription factors that have distinct roles in regulating cell proliferation and differentiation. Previously, our laboratory demonstrated that ERalpha exhibits stereoselective ligand binding and transactivation for several structural derivatives and metabolites of the synthetic estrogen diethylstilbestrol. We have previously described the properties of indenestrol A (IA) enantiomers on ERalpha. In the study presented here, the estrogenic properties of the S and R enantiomers of IA, IA-S and IA-R, respectively, were expanded to examine the activity in different cell and promoter contexts using ERalpha and ERbeta. Using human cell lines stably expressing either ERalpha or ERbeta, we found that IA-S was a more potent activator of transcription than IA-R through ERalpha in human endometrial Ishikawa and breast MDA-MB 231 (MDA) cells. Interestingly, IA-R was more potent on ERbeta when compared with ERalpha in MDA, but not in Ishikawa cells, and IA-R exhibited equally low binding affinities to ERalpha and ERbeta in vitro in contrast to its cell line-dependent preferential activation of ERbeta. Alignment of the protein structures of the ligand-binding domains of ERalpha and ERbeta revealed one mismatched residue, Leu-384 in ERalpha and Met-283 in ERbeta, which may be responsible for making contact with the methyl substituent at the chiral carbon of IA-S and IA-R. Mutagenesis and exchange of this one residue showed that the binding of IA-R and IA-S was not affected by this mutation in ERalpha and ERbeta. However, in transactivation studies, IA-R showed higher potency in activating L384M-mutated ERalpha and wild-type ERbeta compared with wild-type ERalpha and M283L-mutated ERbeta in all cell and promoter contexts examined. Furthermore, IA-R-bound ERalpha L384M and wild-type ERbeta displayed enhanced interactions with the nuclear receptor interaction domains of the coactivators SRC-1 and GRIP1. These data demonstrate that a single residue in the ligand-binding domain determines the stereoselectivity of ERalpha and ERbeta for indenestrol ligands and that IA-R shows cell type selectivity through ERbeta.
两种已知的雌激素受体,即雌激素受体α(ERα)和雌激素受体β(ERβ),是激素诱导型转录因子,在调节细胞增殖和分化中具有不同作用。此前,我们实验室证明,ERα对合成雌激素己烯雌酚的几种结构衍生物和代谢物表现出立体选择性配体结合和反式激活作用。我们之前描述过茚雌酚A(IA)对映体在ERα上的特性。在本文介绍的研究中,将IA的S型和R型对映体(分别为IA-S和IA-R)的雌激素特性进行扩展,以使用ERα和ERβ在不同细胞和启动子环境中检测其活性。利用稳定表达ERα或ERβ的人细胞系,我们发现,在人子宫内膜 Ishikawa 细胞和乳腺 MDA-MB 231(MDA)细胞中,IA-S通过ERα比IA-R是更强效的转录激活剂。有趣的是,在MDA细胞中,与ERα相比,IA-R对ERβ更具活性,但在Ishikawa细胞中并非如此,并且与IA-R对ERβ的细胞系依赖性优先激活作用相反,IA-R在体外对ERα和ERβ表现出同样低的结合亲和力。ERα和ERβ配体结合域的蛋白质结构比对揭示了一个错配残基,ERα中的亮氨酸-384和ERβ中的甲硫氨酸-283,这可能负责与IA-S和IA-R手性碳上的甲基取代基接触。对这一个残基进行诱变和交换表明,IA-R和IA-S的结合不受ERα和ERβ中该突变的影响。然而,在反式激活研究中,在所有检测的细胞和启动子环境中,与野生型ERα和M283L突变的ERβ相比,IA-R在激活L384M突变的ERα和野生型ERβ方面表现出更高的活性。此外,与IA-R结合的ERα L384M和野生型ERβ与共激活因子SRC-1和GRIP1的核受体相互作用域表现出增强的相互作用。这些数据表明,配体结合域中的一个残基决定了ERα和ERβ对茚雌酚配体的立体选择性,并且IA-R通过ERβ表现出细胞类型选择性。